For the Inventor, By the Inventor

Enter assignee name

Hayward, CA, United States of America

Arcus Biosciences, Inc.

USPTO Granted Patents = 40

EPO Patents = 9

Forward Citations = 84

Loading Chart...

Loading Chart...

79 inventors (with patents filed for the assignee):

Manmohan Reddy Leleti (29 out of 72 patents)

Jay Patrick Powers (26 out of 126 patents)

Brandon Reid Rosen (19 out of 20 patents)

4. Kenneth Victor Lawson (18 out of 19 patents)

5. Dillon Harding Miles (18 out of 19 patents)

6. Jaroslaw Kalisiak (15 out of 33 patents)

7. Erick Allen Lindsey (13 out of 13 patents)

8. Ehesan Ul Sharif (13 out of 14 patents)

9. Joel Worley Beatty (11 out of 12 patents)

10. Jenna Leigh Jeffrey (11 out of 12 patents)

11. Eric Newcomb (10 out of 10 patents)

12. Debashis Mandal (8 out of 14 patents)

13. Laurent Pierre Paul Debien (8 out of 8 patents)

14. Samuel Lawrie Drew (7 out of 7 patents)

15. Guillaume Mata (7 out of 7 patents)

40 patents: Sort by Forward Citations

1. 12668635 - METHODS OF TREATING SOLID TUMORS USING AN ANTI-PD-1 ANTIBODY OR A FRAGMENT THEREOF (2026-06-30),

2. 12649751 - Inhibitors of HPK1 and methods of use thereof (2026-06-09),

3. 12630562 - Piperidylurea compounds and methods of use thereof (2026-05-19),

4. 12630526 - Processes for preparing aminopyrimidine compounds (2026-05-19),

5. 12459967 - Modulators of 5'-nucleotidase, ecto and the use thereof (2025-11-04),

6. 12453738 - Treatment of oncogene-driven cancers (2025-10-28),

7. 12433836 - Parenterally administered immune enhancing drugs (2025-10-07),

8. 12415854 - Antibodies to TIGIT (2025-09-16),

9. 12410170 - 2,3,5-trisubstituted pyrazolo[1,5-A]pyrimidine compounds (2025-09-09),

10. 12384773 - Thiazole compounds and methods of use thereof (2025-08-12),

11. 12310965 - Treatment of cancer utilizing an identified adenosine fingerprint (2025-05-27),

12. 12281136 - Crystalline forms of a CD73 inhibitor and uses thereof (2025-04-21),

13. 12226425 - Inhibitors of ARG1 and/or ARG2 (2025-02-18),

14. 12195482 - Compounds as inhibitors of AXL (2025-01-14),

15. 12195447 - Azolopyrimidine for the treatment of cancer-related disorders (2025-01-14),

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies. With a deep understanding of the human immune system's complex biology, the company aims to develop breakthrough treatments for patients suffering from various types of cancer. Arcus Biosciences is committed to harnessing the power of immune cells to combat cancer by targeting critical pathways and enhancing immune response. Through rigorous research and strategic partnerships, the company is dedicated to improving patient outcomes and revolutionizing cancer treatment.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Arcus Biosciences, Inc.

40 Patents

#17 in Hayward, CA

#2,034 in California

#8,612 in US

#17,031 in the World

Hayward, CA, United States of America

Arcus Biosciences, Inc.

Forward Citations = 84

79 inventors:

Manmohan Reddy Leleti (29 out of 72 patents)

Jay Patrick Powers (26 out of 126 patents)

Brandon Reid Rosen (19 out of 20 patents)

4. Kenneth Victor Lawson (18 out of 19 patents)

5. Dillon Harding Miles (18 out of 19 patents)

Please report any incorrect information to [email protected]

Loading…